Bioxodes has enrolled first 16 patients in trial with BIOX-101 Completing treatment of first cohort of patients will trigger interim analysis BIOX-101 is a first-in-class drug candidate, a peptide ...

The Federal Reserve on Wednesday moved to lower its benchmark rate by 0.25 percentage points, but said it plans fewer cuts in 2025.

KalVista has an estimated pro forma cash balance of $292.2 million, which is expected to fund its operations into the 2H of ...

But it might also trigger feelings of nausea. Another theory is that GLP-1s (glucagon-like peptide ... That said, you might ...